Lyell Immunopharma, Inc. (LYEL)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 3
Do Nothing: fundamentalScore 2 and qualitativeScore 2 are below the required floor of 3, and avgDollarVolume20 is only $2.41M versus the $5M minimum.
Company overview
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company focused on developing CAR T-cell products for hematologic malignancies and solid tumors. Its lead product candidates include rondecabtagene autoleucel for large B-cell lymphoma and LYL273 for metastatic colorectal cancer. The company employs various technologies to enhance CAR T-cell efficacy and reduce exhaustion.
Fundamental
weakLyell's fundamentals are speculative, with no revenue and high cash burn, relying on clinical trial outcomes and future financing.
Clinical-stage cell-therapy developer with a solid near-term cash runway and no traditional debt, but still highly speculative due to ongoing large losses and cash burn. Earnings- and revenue-based valuation is not very informative today; the investment case is driven by clinical catalysts and future financing/dilution risk.
Sentiment
weakMedia sentiment has cooled, with no significant retail or catalyst-driven momentum currently present.
Near-term coverage is dominated by the Q2 2026 update (announced) plus follow-on focus on cash-burn framing and insider-selling headlines, leaving sentiment roughly flat-to-neutral over the last ~14d (polarity_score ≈ +0.06) after a more bullish 30–90d baseline (≈ +0.46). Legal/regulatory scans surfaced no cases or regulator-confirmed investigations, but the setup still looks catalyst-light until a new clinical-data or partnership headline appears.
Technical
fairThe stock shows a short-term rebound above key moving averages, but lacks longer-term trend strength.
Score 3/5: LYEL has a credible short-term rebound with price above the SMA20, SMA50, EMA9 and EMA21, while RSI is 61.72 and MACD is positive above signal, but it remains below the SMA200 and the 2026-08-19 close finished below daily VWAP after an intraday fade.
You’re looking at 2026-08-19 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.